AbbVie to present new data from HCV study

Later today, AbbVie (ABBV -1.3%) will present more data from PEARL-1, the Phase 2b study of ABT-450/r — a collaborative effort with Enanta Pharmaceuticals (ENTA -0.2%) — in combination with ABT-267.

95% of GT-1b treatment-naïve patients and 90% of prior null responders achieved SVR12. (PR)

More on recent developments in new HCV treatments here.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs